Case Report

Silicone-Induced Granulomatous Reaction Causing Severe Hypercalcemia: Case Report and Literature Review

Gulshan Man Singh Dangol¹,² and Hilmer Negrete¹,²

¹Department of Internal Medicine, St. Elizabeth Health Center, Youngstown, Ohio, USA
²Department of Internal Medicine, Northeastern Ohio Medical University, Rootstown, Ohio, USA

Correspondence should be addressed to Gulshan Man Singh Dangol; gulshanms@gmail.com

Received 25 September 2018; Accepted 20 December 2018; Published 8 January 2019

1. Introduction

Hypercalcemia is a common electrolyte abnormality with multiple etiologies, including hyperparathyroidism and malignancy [1]. Rare causes, accounting for less than 10% of cases, should be entertained when more prevalent etiologies have been eliminated. One such cause is extra-renal production of 1,25-hydroxy (OH) vitamin D (calcitriol) produced by silicone-induced foreign body granulomas, siliconomas [2–13].

Silicone, chemically inert, has been used for cosmetic enhancement either in the form of liquid silicone injections (LSI) or as silicone filled breast implants (SBI) [14]. In this article, we report a case of silicone-induced hypercalcemia, and review the literature, highlighting the pathophysiology and discuss therapeutic approaches for this exceedingly rare phenomenon.

2. Case

A 67-year-old woman presented to the hospital with complaint of burning epigastric pain over the past two months. Pain was intermittent, non-radiating, and associated with nausea and vomiting. She admitted to unintentional weight loss, approximately 30 pounds, during the past three months. She denied diarrhea, hematemesis, or melena. Significant past surgical history included bilateral silicone breast implants, exploratory laparotomy following gunshot wound with partial bowel resection, Billroth I gastrectomy following peptic ulcer disease, and partial thyroidectomy for a follicular adenoma.

On examination, she appeared pale and severely dehydrated. Vital signs were 141 beats/minute, blood pressure 143/72 mm of Hg, temperature 97.4°F (36.3°C), and respiratory rate 18 breaths/minute. Current weight was 44 kg with a body mass index of 18.3 kg/m². A right-sided thyroid lump was palpable, firm in consistency with regular margins, and moved with swallowing. Breast implants were “rock hard” in consistency with loss of distinct margin over the lower part of the right implant. Heart and lungs were clear to auscultation. Abdomen was soft with multiple surgical scars from previous surgeries. There was mild tenderness over the epigastric region without any guarding or rigidity. There was...
no rebound tenderness. Stool guaiac was weakly positive. Multiple fixed hard masses were palpable over both arms and thighs, but not painful, tender, or erythematous (Figures 1 and 2). On further questioning, she described right breast implant rupture diagnosed several years previous, but did not seek any medical advice because of financial issues.

Admission blood work revealed severe hypercalcemia, Ca 18.4 mg/dL (normal: 8.6-10.2 mg/dl), and hyperphosphatemia, Phosphorus 6.8 mg/dL (normal: 2.5-4.5 mg/dl). Initial differential diagnosis for hypercalcemia included excessive antacid use, hyperparathyroidism, malignancy, and vitamin D intoxication. She denied any antacid use, but reported vitamin D 5000 U supplementation twice daily for the past five years. Parathyroid hormone was low, 13 pg/mL (normal 15-65 pg/mL); parathyroid hormone-related peptide, was normal, <2 pmol/L (normal 0.0 – 3.4 pmol/L); serum and urine protein electrophoresis were both normal; and 25-hydroxy (OH) vitamin D was 40 ng/mL (normal 30-100 ng/mL). Esophagogastroduodenoscopy (EGD) and computed tomography (CT) of the chest and abdomen were negative for malignancy. EGD revealed moderate chronic gastritis; biopsies returned negative for Helicobacter pylori or intestinal metaplasia. Chest CT showed clear lung fields with stable bilateral pulmonary nodules, 3-5 mm, in the lower lobes. X-rays of the arms (Figure 3) and thighs revealed extensive soft tissue calcifications. Biopsy of the thyroid mass demonstrated benign-appearing follicular cells with abundant colloid, negative for malignancy. Abdominal CT was negative for any acute intra-abdominal pathology but showed universal calcnosis bilaterally affecting the musculature of the upper thighs. Colonoscopy demonstrated a hyperplastic polyp with evidence of melanosis coli; no malignant cells were seen.

Serum 1,25-OH vitamin D was very elevated 290.7 pg/mL (normal 19.9-79.3 pg/mL), raising the suspicion of an underlying granulomatous disease. Angiotensinogen converting enzyme was mildly elevated, 137 U/L (Normal 9-67 U/L). Tissue biopsy of soft tissue calcifications was discussed; however, the patient refused. She was managed symptomatically and discharged home. Approximately three months later, the patient was re-admitted with hypercalcemia, 17.4 mg/dL. Abdominal CT scan revealed a 7 mm right sided ureteral calculus with mild hydronephrosis. Need for tissue biopsy was re-discussed with the patient and she agreed. Biopsy of the calcified mass on the left arm demonstrated dystrophic calcifications and foreign body granulomatous reaction (Figure 4).

During initial admission, the patient was managed with intravenous normal saline, subcutaneous calcitonin (4 units/kg) every 12 hours for three doses, and a dose of
pamidronate (60 mg) intravenously. Despite treatment, the patient remained hypercalcemic, 12.8 mg/dL on hospital day 2. An additional dose of intravenous pamidronate (60 mg) was administered, and calcium level improved to 10.8 mg/dL. After hypercalcemia improved, the patient was discharged with consideration for low dose prednisone on an outpatient basis. However, she failed to follow-up.

On her second admission, three months later, she underwent right ureteral lithotripsy with placement of a ureteral stent, in addition to intravenous hydration, calcitonin, and bisphosphonates. After biopsy confirmed foreign body granulomatous reaction, plastic surgery was consulted for removal of breast implants and calcified granulomas. Given extensive extremity distribution of granulomas, surgical excisions were unfeasible. Removal of breast implants was considered but not done because of her financial constraints. The patient was started and maintained on prednisone 20 mg daily. Despite steroid initiation, the patient remained hypercalcemic and was readmitted after one month, a third time, with a serum calcium of 15 mg/dL.

For the past year, she has had multiple admissions with hypercalcemia and its complications (Figure 5). However, after steroid initiation, her hypercalcemic events were less severe.

3. Discussion

Silicone breast implants consist of a silicone gel enclosed within an outer shell, also known as an elastomer, which provides protection against contracture and rupture [15]. However, breast implant rupture may occur following trauma or during mammography. Once ruptured, silicone materials may disperse to distant sites, either through lymphatic or vascular systems.

The immune system can induce a foreign body reaction in response to administration of organic or inorganic materials, leading to chronic granulomatous inflammation. Epidemiological data has suggested higher rates of sarcoidosis in women receiving silicone breast implants [16]. Such reaction has a latent phase, usually following an acute inflammatory phase, and can last several years, prompting delayed clinical presentation. Typical presentation includes hardening of the skin and tissues, formation of lumps and nodules, and occasional ulcerations [17]. Silicone, either in the form of LSI or following SBI rupture, induces granulomatous reaction leading to the formation of foreign body tumors or siliconomas. Formation of siliconomas following silicone use was first described by Winer et al. in 1964 [18]. However, siliconomas causing hypercalcemia are extremely rare; only a handful of cases have been reported in the literature. Kozeny et al., in 1984, published the first incident of this rare condition [2]. Subsequently, thirteen cases have been reported (Table 1) [2–13]. Most of the cases reported were female; four were transgender. LSI were used in most cases with or without the implantation of SBI. In only one case, SBI was identified as the sole cause of hypercalcemia [10]. Also reported was the use of silicone with the help of transdermal ultrasound to remove wrinkles from the face and neck in one of the cases [5]. Hydration and steroids, with or without bisphosphonates, were the mainstay of treatment, but with improvement in only five cases [3, 5, 6, 12, 13]. Surgical excision of silicone granulomas helped normalize serum calcium in two of the reported cases, [9] and removal of breast implants resulted in improvement in one case [10]. The current case is the second case involving hypercalcemia solely secondary to SBI rupture. While our patient denied any LSI use, including on follow-up, silicone from implant rupture alone may be insufficient in quantity to cause the clinical and radiological findings. Typically, SBI ruptures contribute to local inflammation, and blood or lymphatic silicone transport is microscopic. However, distant multiple siliconomas in lower extremities following breast implant rupture have been described [19]. Among the cases reported, the current case has the highest serum calcium level reported. Use of steroid resulted in temporary improvement, and removal of granulomas and SBI were not pursued in our case.

The exact mechanism of silicone induced hypercalcemia is unknown. Formation of foreign-body granulomas by silicone may play a role in producing hypercalcemia. Granulomatous diseases, especially sarcoidosis, are known to cause calcitriol-related hypercalcemia. In these disorders, macrophages are known to produce 1-alpha-hydroxylase, responsible for the conversion of inactive vitamin D to its active form. Postulated pathophysiology includes the immunomodulatory effect of calcitriol, which decreases T-cell activity at the site of inflammation, probably by inhibiting interleukin-2 and γ-interferon [20]. In addition, immunohistochemical studies in vitro have demonstrated 1-alpha-hydroxylase activity in macrophages of sarcoid and foreign-body granulomas [20, 21].

Normally, the enzyme 1-alpha-hydroxylase is present in renal tubular cells, regulating the production of calcitriol. High serum levels of calcitriol cause negative feedback, leading to inhibition of 1-alpha-hydroxylase enzyme. However, these regulatory mechanisms are deficient in macrophages, resulting in unregulated 1,25-OH vitamin D production [18]. This unregulated extra-renal production of calcitriol causes
Table 1: Literature reported hypercalcemia cases following use of cosmetic silicone.

| Authors (year)       | Age (years) | Sex   | Site of silicone administration | Serum Calcium (mg/dL) | 1,25-OH vitamin D (pg/mL) | Treatment received | Overall outcome                                                                 |
|----------------------|-------------|-------|----------------------------------|-----------------------|---------------------------|-------------------|--------------------------------------------------------------------------------|
| Kozeny, et al. (1984)| 33          | Transgender | Silicone injections to face, breasts and both hips | 14.7                  | 85.0                       | Hydration and steroids | Serum calcium improved while on steroid, but increased after it was stopped |
| Singapuri, et al. (2010) | 49         | Female | Silicone injections to gluteal region | 14.6                  | NA*                       | Hydration, bisphosphonates and steroids | Serum calcium stabilized                                                          |
| Ogbuagu, et al. (2010) | 38         | Female | Silicone breast implants; silicone injections to lips, hip and breasts | 14.0                  | 51.0                       | NA*               | NA*                                                                            |
| Ogbuagu, et al. (2010) | 48         | Transgender | Silicone injections to hips, face and breasts | 11.8                  | 63.0                       | NA*               | NA*                                                                            |
| Schanz, et al. (2012) | 72          | Female | Topical silicone applied over face and neck with transdermal ultrasound for wrinkles removal | 12.1                  | 39.0                       | Steroids           | Serum calcium normalized                                                          |
| Agrawal, et al. (2013) | 45          | Transgender | Bilateral breast implants and silicone injections to buttocks | 13.1                  | 147.0                      | Hydration and steroids | Serum calcium normalized                                                          |
| Camuzard, et al. (2014) | 63         | Female | Silicone injections to buttocks and hips | 13.0                  | 65.0                       | Hydration, bisphosphonates and steroids | No improvement in serum calcium, patient refused surgical treatment |
| Visnyei, et al. (2014) | 40          | Transgender | Silicone injections to thigh and gluteal region | 12.3                  | 47.0                       | Hydration, bisphosphonates and steroids | Initial improvement in serum calcium, but noncompliance resulted in elevation of serum calcium |
| Authors (year) | Age (years) | Sex | Site of silicone administration | Serum Calcium (mg/dL) | 1,25-OH vitaminD (pg/mL) | Treatment received | Overall outcome |
|----------------|-------------|-----|---------------------------------|-----------------------|--------------------------|-------------------|----------------|
| Edwards, et al (2015) | 50 | Female | Silicone injections to gluteal region | 17.3 | 71.0 | Steroid and pentoxiphylline; surgical removal of granulomas | Steroid and pentoxiphylline did not help; surgical removal of granulomas normalized serum calcium |
| Edwards, et al. (2015) | NA | Female | Silicone injections to gluteal region | 11.5 | 89.0 | Steroids and surgical excision of silicone granulomas | Surgical excision improved serum calcium levels |
| Melnick et al. (2016) | 41 | Female | Silicone injections to buttocks | 13.5 | 84.0 | IV hydration, pamidronate | Serum calcium improved at one year followup |
| Rodriguez, et al. (2017) | 74 | Female | Silicone breast implants | 14.0 | NA* | Hydration, calcitonin and removal of breast implants | Improvement in serum calcium |
| Noreña, et al. (2017) | 40 | Female | Silicone injections to gluteal region | 13.0 | 69.1 | Hydration, calcitonin, bisphosphonates, sevelamer, chloroquine, and steroids | No improvement in serum calcium, patient died from complications of hypercalcemia |
| Hamadeh, et al. (2018) | 35 | Male | Silicone injections to shoulder, arms and forearms | 13.1 | 19.3 | Massexcision; hydration, and tapering course of steroids (40 mg daily for three weeks, tapered by 5 mg weekly thereafter) | Improvement in serum calcium |
| Dangol, et al. (current case) (2018) | 67 | Female | Silicone breast implants | 18.4 | 290.7 | Hydration, calcitonin, bisphosphonate and steroids | No improvement in serum calcium; multiple admissions with hypercalcemia and its complications |

*NA = not available.
**Across the series, normal range for serum calcium was 8.2 – 10.3 mg/dL.
***Across the series, normal range for 1,25-OH vitamin D was 15.0 – 86.5 pg/ml.
increased intestinal absorption and calcium mobilization from bones, resulting in hypercalcemia.

Definitive treatment of silicone-induced hypercalcemia is unknown. The benefit of targeted monoclonal antibody treatment for molecular pathways, especially in interleukin production, is unknown, but may be beneficial in the fibrotic phase of silicone induced reactions [22]. Unlike sarcoidosis, where corticosteroids markedly improve production of 1,25-OH vitamin D, treatment with steroids is of limited value in silicone-induced hypercalcemia. While the addition of steroids and removal of foreign body granulomas and implants were helpful in some cases, no treatment modalities or response was noted in other cases. In our patient, steroids were of minimal benefit; removal of granulomas was unfeasible, given extensive dissemination. While steroids may decrease hypercalcemia severity, the adverse profile of steroids over long periods raises the question of possible risk versus benefit. Silicone-induced foreign-body granulomatous reaction should be considered in patients who have undergone cosmetic enhancement and developed hypercalcemia. Treating physicians should be aware of limited treatment modalities available for silicone hypercalcemia and educate individuals of the risk of silicone cosmesis.

Conflicts of Interest

The authors have no conflicts of interest to report.

Acknowledgments

The authors wish to thank David Gemmel, Ph.D. for critique, manuscript review, and editing.

References

[1] F. W. Laflery, "Differential diagnosis of hypercalcemia," Journal of Bone and Mineral Research, vol. 6, pp. S51–S59, 1991.
[2] G. A. Kozeny, A. L. Barbato, V. K. Bansal, L. L. Vertuno, and J. E. Hano, "Hypercalcemia associated with silicone-induced granulomas," The New England Journal of Medicine, vol. 311, no. 17, pp. 1103–1105, 1984.
[3] S. Singapuri, D. Patel, and F. Rahbari-Oskoui, "285: Hypercalcemia Associated With Gluteal Silicone Injections: A Case Report," American Journal of Kidney Diseases, vol. 55, article B103, 2010.
[4] O. Ogbugu, P. Soltani, K. Lawrence, and A. Stern, "216: Unique Etiology of Hypercalcemia in Male to Female Transgender Patients," American Journal of Kidney Diseases, vol. 55, no. 4, p. B85, 2010.
[5] J. Schanz, K. Flux, C. Kircher et al., "Mirror, mirror on the wall: Hypercalcemia as a consequence of modern cosmetic treatment with liquid silicone," Medical Science Monitor, vol. 18, pp. CS5–CS7, 2012.
[6] N. Agrawal, S. Altiner, N. H. E. Mezitis, and S. Helbig, "Silicone-induced granuloma after injection for cosmetic purposes: A rare entity of calcitriol-mediated hypercalcemia," Case Reports in Medicine, vol. 2013, pp. 1–3, 2013.
[7] O. Camuzard, P. Dumas, R. Foissac et al., "Severe granulomatous reaction associated with hypercalcemia occurring after silicone soft tissue augmentation of the buttocks: A case report," Aesthetic Plastic Surgery, vol. 38, no. 1, pp. 95–99, 2014.
[8] K. Visnyei, M. Samuel, L. Heacock, and J. A. Cortes, "Hypercalcemia in a male-to-female transgender patient after body contouring injections: A case report," Journal of Medical Case Reports, vol. 8, article 71, 2014.
[9] B. J. Edwards, S. Saraykar, M. Sun, W. A. Murphy, P. Lin, and R. Galgel, "Resection of granulomatous tissue resolves silicone induced hypercalcemia," Bone Reports, vol. 5, pp. 163–167, 2016.
[10] I. E. Rodriguez and F. W. Deleyiannis, "Hypercalcemia secondary to silicone breast implant rupture," Plastic and Reconstructive Surgery - Global Open, vol. 5, article e1416, 2017.
[11] J. A. Noreña, C. D. Niño, S. Gallego et al., "Calcitriol-mediated hypercalcemia secondary to granulomatous disease caused by soft-tissue filler injection: A case report," Clinical Cases in Mineral and Bone Metabolism, vol. 14, pp. 340–346, 2017.
[12] M. Hamadeh, J. Fares, K. Maoutk et al., "Hypercalcemia in a bodybuilder with cosmetic silicone injections," The New Zealand Medical Journal, vol. 131, pp. 78–81, 2018.
[13] S. Melnick, A. Abarao-Salvatierra, M. Deshmukh, and A. Patel, "Calcitriol mediated hypercalcemia with silicone granulomas due to cosmetic injection," BMJ Case Reports, 2016, online accessed 12/15/2018.
[14] P. E. Chasan, "The history of injectable silicone fluids for soft-tissue augmentation," Plastic and Reconstructive Surgery, vol. 120, no. 7, pp. 2034–2040, 2007.
[15] M. Grigg, S. Bondurant, V. L. Ernster et al., Information for Women about the Safety of Silicone Breast Implants, National Academies Press, Washington, DC, USA, 2000.
[16] A. Watad, V. Rosenberg, S. Tiosano et al., "Silicone breast implants and the risk of autoimmune/rheumatic disorders: a real-world analysis," International Journal of Epidemiology, vol. 47, no. 6, pp. 1846–1854, 2018.
[17] M. J. Rapaport, C. Vinnik, and H. Zarem, "Injectable silicone: Cause of facial nodules, cellulitis, ulceration, and migration," Aesthetic Plastic Surgery, vol. 20, pp. 267–276, 1996.
[18] L. H. Winer, T. H. Sternberg, R. Lehman, and F. L. Ashley, "Tissue reactions to injected silicone liquids," Arch Dermatol, vol. 90, pp. 588–592, 1964.
[19] J. H. Oh, S. Y. Song, D. H. Lew, and D. W. Lee, "Distant migration of multiple siliconomas in lower extremities following breast implant rupture," Plastic and Reconstructive Surgery - Global Open, vol. 4, pp. 1–3, 2016.
[20] M. Conron, C. Young, and H. L. C. Beynon, "Calcium metabolism in sarcoidosis and its clinical implications," Rheumatology, vol. 39, pp. 707–713, 2000.
[21] A. G. Moraitis, M. Hewison, M. Collins, C. Anaya, and M. F. Holick, "Hypercalcemia associated with mineral oil-induced sclerosing panarteritis," Endocrine Practice, vol. 19, pp. 50–56, 2013.
[22] A. M. Desai, J. Browning, and T. Rosen, "Etanercept therapy for silicone granuloma," Journal of Drugs in Dermatology, vol. 5, pp. 894–896, 2006.